These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 16465917)

  • 1. [Breast cancer cell populations and its changes relation to therapy].
    Kolarík D; Netíková L; Marinov I; Julis I; Halaska M; Raus K; Driák D; Záhumenský J; Benková K; Halaska M
    Ceska Gynekol; 2006 Jan; 71(1):43-60. PubMed ID: 16465917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
    Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
    Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
    Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
    Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
    Yeo B; Dowsett M
    Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does HER-2 status predict only a decreased response to hormone therapy in advanced breast cancer, or does it also predict the extent of metastatic disease?
    Beltràn M; Colomer R
    J Clin Oncol; 2002 Dec; 20(23):4605; author reply 4606. PubMed ID: 12454123
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
    Calhoun BC; Collins LC
    Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.
    Cirak Y; Furuncuoglu Y; Yapicier O; Alici S; Argon A
    Int J Clin Exp Pathol; 2015; 8(5):5345-53. PubMed ID: 26191236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer.
    Patani N; Jiang W; Mokbel K
    Int J Cancer; 2008 Jun; 122(11):2646. PubMed ID: 18302153
    [No Abstract]   [Full Text] [Related]  

  • 11. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
    Wang-Lopez Q; Chalabi N; Abrial C; Radosevic-Robin N; Durando X; Mouret-Reynier MA; Benmammar KE; Kullab S; Bahadoor M; Chollet P; Penault-Llorca F; Nabholtz JM
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):88-104. PubMed ID: 25900915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor markers of breast cancer].
    Sławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognostic value of vascular endothelial growth factor in breast cancer].
    Jing J; Zhao Y; Li H; Zhang S; Shi Z
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):566-8. PubMed ID: 12528550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
    Nakajima N; Kataoka M; Sugawara Y; Ochi T; Kiyoto S; Ohsumi S; Mochizuki T
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):738-46. PubMed ID: 24064322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    Duffy MJ; Walsh S; McDermott EW; Crown J
    Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.
    Elledge RM; McGuire WL
    Annu Rev Med; 1993; 44():201-10. PubMed ID: 8476242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
    Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of E-cadherin and bcl-2 on prognosis in patients with breast cancer.
    Kavgaci H; Yildiz B; Fidan E; Reis A; Ozdemir F; Cobanoglu U; Can G
    Bratisl Lek Listy; 2010; 111(9):493-7. PubMed ID: 21180263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.